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Abstract
Background: Respiration-gated radiotherapy can permit the irradiation of smaller target volumes.
4DCT scans performed for routine treatment were retrospectively analyzed to establish the
benefits of gating in stage III non-small cell lung cancer (NSCLC).
Materials and methods: Gross tumor volumes (GTVs) were contoured in all 10 respiratory
phases of a 4DCT scan in 15 patients with stage III NSCLC. Treatment planning was performed
using different planning target volumes (PTVs), namely: (i) PTVroutine, derived from a single GTV plus
'conventional' margins; (ii) PTVall phases incorporating all 3D mobility captured by the 4DCT; (iii)
PTVgating, incorporating residual 3D mobility in 3–4 phases at end-expiration. Mixed effect models
were constructed in order to estimate the reductions in risk of lung toxicity for the different PTVs.
Results: Individual GTVs ranged from 41.5 – 235.0 cm3. With patient-specific mobility data (PTVall
phases), smaller PTVs were derived than when 'standard' conventional margins were used (p <
0.001). The average residual 3D tumor mobility within the gating window was 4.0 ± 3.5 mm, which
was 5.5 mm less than non-gated tumor mobility (p < 0.001). The reductions in mean lung dose were
9.7% and 4.9%, respectively, for PTVall phases versus PTVroutine, and PTVgating versus PTVall phases. The
corresponding reductions in V20 were 9.8% and 7.0%, respectively. Dosimetric gains were smaller
for primary tumors of the upper lobe versus other locations (p = 0.02). Respiratory gating also
reduced the risks of radiation-induced esophagitis.
Conclusion: Respiration-gated radiotherapy can reduce the risk of pulmonary toxicity but the
benefits are particularly evident for tumors of the middle and lower lobes.
Background
As lung tumors can show significant respiration-induced
motion [1,2], sufficient margins have to be added to
account for target mobility in radiotherapy planning [3].
For stage I non-small cell lung cancer (NSCLC), com-
monly used 'population-based' margins result in unneces-
sary irradiation of significant amounts of normal tissue
[2,4], thereby increasing the risk of toxicity. For stage III
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NSCLC, local control after radiotherapy is poor [5,6], and
both radiation dose-escalation and concurrent chemo-
radiotherapy schemes have been used in an attempt to
improve local control. However, such approaches can
increase late radiation-induced toxicity [7-11], and reduc-
tions in treated volumes may help in reducing toxicity.
Respiration-correlated (or 4D) CT scans permit an indi-
vidualized assessment of tumor mobility [12]. Respiratory
gating enables smaller target volumes to be used as treat-
ment delivery is restricted to predetermined phases of res-
piration, during which tumor mobility is relatively
limited. However, planning and delivery of gated radio-
therapy requires reliable data on intra- and inter-frac-
tional tumor mobility. In stage I NSCLC, individualized
planning target volumes (PTVs) that incorporated all
tumor mobility or the residual mobility in three end-
expiratory phases allowed for mean PTV reductions of
48.2% and 33.3%, respectively, relative to standard mar-
gins [2]. The magnitude of benefit that can be achieved
with gating in stage I tumors was found to correlate with
the extent of mobility.
A recent study in patients with stage III NSCLC reported
that limited decreases in lung doses could be achieved
with gating, but only if GTVs did not exceed 100–150 cm3
[13]. However, tumor mobility in this study was derived
from breath-hold CT scans at full inspiration and tidal
end-expiration. A more realistic analysis requires knowl-
edge of mobility in all phases of quiet respiration, i.e.
4DCT data. We retrospectively analyzed 4D datasets in
order to determine the geometric and dosimetric benefits
of respiration-gated radiotherapy in stage III NSCLC.
Methods
The 4DCT scans of 15 consecutive patients with stage III
NSCLC who were treated with conventionally fraction-
ated involved-field radiotherapy at the VU University
medical center, were retrospectively analyzed. The pri-
mary tumors were located in the upper (n = 9), middle (n
= 2) and lower lobe (n = 4), respectively. Patient charac-
teristics are summarized in Table 1. All patients had at
least one metastatic N2-3 lymph node, and nodal loca-
tions were described according to Mountain et al. [14].
4DCT scanning procedure
Patients were immobilized in the supine position, with
the arms positioned above the head on an adjustable arm
support and a knee rest device was used (Posirest-2 and
Kneefix cushion device, Sinmed, Reeuwijk, The Nether-
lands). A 4DCT thoracic scan was performed during
uncoached quiet respiration on a 16 slice CT scanner. A
respiratory monitoring system (Respiratory Position Man-
agement, Varian Medical Systems, Palo Alto, CA) was
used for recording the breathing pattern. A lightweight
block containing two reflective markers is placed on the
upper abdomen, typically halfway between the xiphoid
and umbilicus, and infrared light from an illuminator is
reflected from the markers, and captured by a camera.
Our 4DCT protocol for scanning lung tumors has been
reported in detail previously [12]. Briefly, 8 contiguous
slices of 2.5 mm are generated for a 2 cm total longitudi-
nal coverage per gantry rotation with the scanner operated
in axial cine mode. Other scanning parameters include
140 KV, 95 mA and tube rotation set closest to 1/10 of the
average breathing cycle time to allow high temporal and
Table 1: Patient characteristics
Patient TNM-stage Primary tumor location Lymph node locations GTV (cc)
1T 2N2M0 Right upper lobe 2R, 4R 101.4
2T 3N2M0 Left upper lobe 4L 231.6
3T 2N3M0 Right upper lobe 4R, 4L 63.6
4T 2N2M0 Right lower lobe 7 77.9
5T 3N3M0 Right upper lobe 4R, 4L 174.7
6T 2N2M0 Right lower lobe 4R 99.1
7T 3N2M0 Right lower lobe 4R, 7 61.7
8T 2N2M0 Right upper lobe 4R 74.8
9T 1N3M0 Right middle lobe 4R, 4L 71.8
10 T2N2M0 Left lower lobe 4L, 7 180.9
11 T4N3M0 Right upper lobe 4L 154.6
12 T2N2M0 Left upper lobe 2L, 4L 41.5
13 T2N3M0 Right upper lobe 2R, 4R, 4L 84.2
14 T3N2M0 Left upper lobe 4L 235.0
15 T3N2M0 Right middle lobe 2R, 4R, 7 164.3
GTV = gross tumor volume
Lymph node locations are according to Mountain et al. [20].Radiation Oncology 2006, 1:8 http://www.ro-journal.com/content/1/1/8
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spatial resolution. With the scanner couch in static mode,
data is acquired for at least the duration of one full respi-
ratory cycle, after which the couch advances to the next
position. Data acquisition ceases during the couch move-
ment, and a full 4DCT scanning procedure of the thorax
generally takes about 90 seconds. The radiation exposure
from the 4DCT acquisition is about 52.7 mGy in CTDIvol
when the patients' breathing cycle is 4 sec, which is about
6 times the dose of our single conventional helical CT
scan procedure. Retrospective sorting of the images into
spatio-temporally coherent volumes is performed using
4D software (Advantage 4D, GE Medical Systems, Wauke-
sha, WI). Each reconstructed image is assigned to a spe-
cific respiratory phase (or 'bin') based on the temporal
correlation between surface motion and data acquisition,
and 10 respiratory phases are generated. The actual clini-
cal treatment of these patients was based upon non-gated
treatment delivery to a PTV that incorporated mobility
seen in all phases of respiration (PTVall phases).
In this retrospective analysis, the bins representing all 10
phases of respiration were imported into the radiotherapy
planning system (Eclipse version 6.5, Varian Medical Sys-
tems, Palo Alto, CA). All ten 3D data sets derived from a
4DCT scan shared DICOM coordinates, which simplified
image registration of the data sets using the "shared
DICOM coordinates" option. After image registration, the
position of a vertebra at the level of the primary tumor
was checked to ensure that no patient movement had
occurred during the 4DCT acquisition procedure.
Defining the 'gating- window'
As gating will prolong treatment delivery, it is common to
use a 'gate' that allows a duty cycle of at least between 20–
40% of respiration [15]. In order to identify the gate, all
ten 4DCT bins were imported into the '4D Review' appli-
cation in the Advantage workstation where 3 or 4 consec-
utive 'gating bins' in expiration were simultaneously
viewed in axial, frontal and sagittal reconstructions. A 'gat-
ing window' was identified at end-expiration in which
mobility of the primary tumor and/or hilus was minimal.
The use of longer gating windows improve the efficiency
of treatment delivery, and a total of 4 phases were selected
in 4 patients as review of the 4DCT movies suggested lim-
ited mobility of the primary tumor within in these 'gates'.
Deriving target volumes and contouring critical structures
Gross tumor volumes (GTVs) were contoured in each of
the 10 phases of a 4DCT using standardized lung and
mediastinal window level settings by one clinician in
order to minimize contouring variations. The use of
involved-field radiotherapy is standard practice at our
center for the treatment of stage III NSCLC [16], and the
GTV included the primary tumor, ipsilateral hilus, lymph
nodes with a short axis diameter of 1.0 cm or greater and/
or FDG-PET positive lymph nodes. All contours were
automatically projected onto the second 'bin' in the mid-
dle of the gating window. Similarly, the spinal cord and
esophagus were also contoured in this specific 'gating
bin'. In six patients, the primary tumor and the hilus were
contoured as a single entity as the two structures were
adjacent to each other.
For all 15 patients, three PTVs were generated:
(i) PTVroutine, derived from a phase at the center of the 'gat-
ing window', i.e from a single component CT scan. An iso-
tropic margin of 1.5 cm (but 2.0 cm for cranial and caudal
margins in lower lobe tumors) was added to the GTV in
order to account for microscopic extension, mobility and
set-up inaccuracies;
(ii) PTVall phases, which consisted of the volume encom-
passing all ten GTVs (i.e. all respiration-induced mobil-
ity), plus an isotropic margin of 1.0 cm for microscopic
extension and set-up inaccuracies;
(iii) PTVgating, consisting of the volume encompassing 3–
4 GTVs in the gating window, plus an isotropic margin of
1.0 cm for microscopic extension and set-up inaccuracies.
Analysis of target mobility
A 'bounding box' technique was used to assess the mobil-
ity of GTVs, as was previously reported [17]. Briefly, the
approach involves fitting a rectangular box to each target
volume, and changes in the position of a moving target in
the X-, Y- and Z-axes are derived from the corresponding
sides of the box. The overall 3D displacement of each GTV
was derived using Pythagoras's algorithm.
The following analyses were performed: (i) mobility of
individual GTVs, derived from displacement of a single
GTV (GTVsingle phase) within GTV all phases, (ii) the reduction
in mobility achieved with the use respiratory gating,
derived from calculating the displacement of the GTVgating
within GTVall phases, and (iii) residual GTV mobility within
gating windows, derived from displacement of the GTVsin-
gle phase within GTVgating.
Treatment planning and dosimetric analysis
Treatment planning was performed on each PTVroutine,
PTVall phasesand PTVgating, all of which were projected onto
a single end-expiratory CT set. The study patients were
treated using two different fractionation schemes, namely
60 Gy in 30 fractions and 46 Gy in 23 fractions. The latter
was a dose used for pre-operative concurrent chemo-radi-
otherapy. For both schemes, the PTVs received at least
95% of the prescribed dose, and a dose maximum of
107% of the prescribed dose was accepted unless a higher
dose maximum was located within the PTV. The V20 val-Radiation Oncology 2006, 1:8 http://www.ro-journal.com/content/1/1/8
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ues had to be less than 35%, and dose to spinal cord less
50 Gy. An initial treatment plan was derived for PTVroutine,
and treatment plans for PTVall phases and PTVgating were then
derived by shrinking the fields of the initial plan, without
other changes to the beam setup.
Dose-volume histograms (DVH) were computed for the
total lung minus the volume of PTVgating in order to gener-
ate a reference lung volume that was copied to each treat-
ment plan. The maximum spinal cord dose and predictors
of lung toxicity, the V20 and mean lung dose (MLD) [18],
were evaluated for each plan. The length of the esophageal
circumference encompassed by the 40 Gy and 50 Gy isod-
ose was obtained by visually scrolling through axial CT
slices.
Statistical analysis
The differences between the three PTVs and the reduction
in GTV mobility achieved with gating were evaluated
using the Hodges-Lehman non-parametric test. The exist-
ence of a correlation between the reduction in GTV mobil-
ity with respiratory gating and the dosimetric gains
achieved, were evaluated using the Spearman's non-para-
metric correlation test. In addition, the dosimetric data
was analyzed for differences according to tumor stage and
tumor location (upper vs. non-upper lobe. All statistical
analyses were conducted using the Cytel Studio's StatXact-
6 software (Version 6.2.0).
Finally, mixed effect models were constructed (SAS ver-
sion 8.02 and S-plus version 6.2) in order to estimate the
general dosimetric gains that can be achieved (PTVroutine
vs. PTVall phases; PTVroutine vs. PTVgating; PTVall phases vs. PTV-
gating) on the V20 and MLD, as well as on critical structures
(esophagus and spinal cord).
Results
Volumetric comparison of PTVs
The individual GTVs ranged from 41.52 cc to 235.04 cc,
and six GTVs were larger than 150 cc (Table 1). The PTV-
routine was the largest volume for all patients (Figure 1).
Use of individualized margins led to significantly smaller
Absolute volumes of PTVroutine(● ), PTVall phases() and PTVgating(▲ ) Figure 1
Absolute volumes of PTVroutine(● ), PTVall phases() and PTVgating(▲ ).Radiation Oncology 2006, 1:8 http://www.ro-journal.com/content/1/1/8
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volumes (PTVall phases) than with the use of standard mar-
gins (p < 0.001). The same was observed for PTVgating ver-
sus PTVall phases(p < 0.001).
Mobility of target volumes
The mean mobility of GTVsingle phase within GTVall phases was
9.4 ± 6.3 mm (1 SD) and the data are summarized in
Table 2. With a gating 'duty cycle' extending to 3–4 phases
of the respiratory cycle, mean GTV mobility was reduced
by 5.5 ± 3.8 mm (p < 0.001). The mean "residual" GTV
mobility within the chosen gating window was 4.0 ± 3.5
mm (Table 2), and a residual GTV mobility that exceeded
5.0 mm was observed in 5 patients (33%), including 2
patients with upper lobe lesions. When only tumors of the
middle and lower lobe were evaluated, the mean GTV
mobility in all phases was 13.7 ± 7.1 mm, which
decreased to 5.6 ± 4.6 mm with gating.
Treatment planning
Treatment was planned to a dose of 60 Gy for 11 of the 15
patients. The other four had lesions of the upper lobe that
extended to the contralateral mediastinum, and all these
patients underwent pre-operative chemo-radiotherapy to
46 Gy. Reduction in the risk of pulmonary toxicity with
gating was assessed using dedicated statistical models for
all patients (n = 15) on mean lung dose (MLD) and in 14
patients with respect to the volume of lungs receiving at
least 20 Gy (V20). One patient was excluded from the V20
model as the V20 values of the plans did not meet the V20
inclusion criteria, i.e. V20 (routine) > V20 (all phases) > V20
(gating). In this patient with a right lower lobe tumor, the
V20 (all phases) was larger than the V20 (routine), which
was the result of substantial lateral mobility of the medi-
astinal lymph nodes. Nevertheless, the PTVall phases plan
did meet the inclusion criteria used in the MLD model, i.e.
MLD (routine) > MLD (all phases) > MLD (gating).
The mixed effect model showed that the MLD was
reduced by 9.7%, 4.9% and 14.2%, respectively, for PTVall
phases versus PTVroutine, PTVgating versus PTVall phases and PTV-
gating versus PTVroutine. The corresponding figures for the
V20 were 9.8%, 7.0% and 16.2% (Tables 3, 4). Upper lobe
tumors showed a significantly lower dosimetric gain than
tumors located in other lobes (p = 0.02). When the anal-
ysis was restricted to lower and middle lobe tumors, the
corresponding figures for V20 reduction were 7.2%, 10.1%
and 16.5%, and for reduction in MLD 9.9%, 6.4% and
15.7%, respectively. Tumor stage had no significant influ-
ence on the dosimetric improvements achieved with res-
piratory gating.
As could be expected, a strong correlation was observed
between the reduction in PTV observed with respiratory
gating and the reduction in GTV mobility (Spearman's
Non-parametric correlation test ρ = 0.78, linear regression
coefficient = 4.3 (p < 0.001)). In addition, a correlation
could be demonstrated between the reduction in PTV with
gating and reductions in both in V20 and MLD values (Fig-
ure 2 and 3).
Esophageal and spinal dose parameters
With the use of involved-field radiotherapy, only 11
patients received an esophageal circumference dose of at
least 40 Gy. The mean circumferential length receiving a
Table 2: GTVs and GTV mobility.
Patient GTVall phases (cc) GTVgating (cc) Ungated GTV mobility (mm) Residual GTV mobility (mm)
1 126.9 104.1 5.6 2.2
2 247.4 239.0 1.0 0.0#
3 76.3 68.1 11.2 5.8
4 132.3 90.6 17.3 6.4
5 201.0 183.4 8.2 3.2#
6 128.6 112.5 22.6 14.0#*
7 98.4 66.8 18.2 5.9
8 112.7 81.9 10.9 2.0
9 109.8 79.8 8.4 1.4
10 216.3 193.2 3.0 2.0
11 199.8 162.5 8.7 4.6
12 49.7 44.0 1.0 1.0#
13 97.7 89.0 8.4 6.4
14 254.0 239.3 4.6 1.0
15 240.7 193.3 12.6 3.6
Mean 152.8 129.8 9.4 4.0
SD 67.1 65.5 6.3 3.5
# gating-window incorporated four successive phase bins.
* mainly due to residual nodal mobility in the mediastinumRadiation Oncology 2006, 1:8 http://www.ro-journal.com/content/1/1/8
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dose of 40 Gy was 6.8 ± 2.3 cm for PTVroutine. Use of PTVall
phases reduced this value by a mean of 0.8 cm, and the
reduction with PTVgating was 1.2 cm, both proved signifi-
cant (Satterthwaite approximation for the denominator
degrees of freedom used to give accurate F approxima-
tions). A circumferential dose of 50 Gy was seen in 8
patients, and the mean esophageal circumference receiv-
ing 50 Gy was 5.3 ± 2.0 cm for PTVroutine. Use of PTVall
phases and PTVgating reduced this value by a mean of 1.8 and
2.3 cm, respectively (p < 0.001, Page T: k-tuple non-para-
metric exact test for grouped data).
Table 4: Reduction in V20 (%) using different PTV definitions.
V20 (%) Absolute V20 (%) and relative (%) reduction in V20
Patient PTVroutine PTVall phases vs. PTVroutine PTVgating vs. PTVroutine PTVgating vs. PTVall phases
1 38.0 4.1 (10.8%) 5.1 (13.4%) 1.0 (2.9%)
2 27.1 2.2 (8.1%) 3.5 (12.9%) 1.3 (5.2%)
3 29.0 2.0 (6.9%) 2.8 (9.7%) 0.8 (3.0%)
4 31.0 3.8 (12.3%) 6.7 (21.6%) 2.9 (10.7%)
5 26.1 2.2 (8.4%) 2.9 (11.1%) 0.7 (2.9%)
6 28.9 -1.5 (-5.2%) 0.1 (0.3%) 1.6 (5.3%)
7 26.2 0.9 (3.4%) 4.3 (16.4%) 3.4 (13.4%)
8 20.5 3.7 (18%) 4.4 (21.5%) 0.7 (4.2%)
9 28.2 1.7 (6.0%) 4.8 (17.0%) 3.1 (11.7%)
10 27.5 4.2 (15.3%) 6.5 (23.6%) 2.3 (9.9%)
11 27.6 2.4 (8.7%) 4.9 (17.8%) 2.5 (9.9%)
12 25.5 4.4 (17.3%) 4.9 (19.2%) 0.5 (2.4%)
13 28.8 2.9 (10.1%) 6.0 (20.8%) 3.1 (12.0%)
14 23.9 3.7 (15.5%) 4.2 (17.6%) 0.5 (2.5%)
15 42.8 5.0 (11.7%) 8.6 (20.1%) 3.6 (9.5%)
Mean 28.7 2.8 (9.8%) 4.6 (16.2%) 1.9 (7.0%)
SD 5.4 1.7 (5.9%) 2.0 (6.0%) 1.2 (4.1%)
Table 3: Reduction in mean lung dose (Gy) using different PTV definitions.
Mean lung dose (Gy) Absolute (Gy) and relative (%) reduction in mean lung dose
Patient PTVroutine PTVall phases vs. PTVroutine PTVgating vs. PTVroutine PTVgating vs. PTVall phases
1 25.2 2.7 (10.7%) 3.6 (14.3%) 0.9 (4.0%)
2 20.6 1.6 (7.8%) 2.4 (11.7%) 0.8 (4.2%)
3 18.9 1.6 (8.5%) 2.2 (11.6%) 0.6 (3.5%)
4 23.0 1.3 (5.7%) 3.0 (13.0%) 1.7 (7.8%)
5 12.8 1.1 (8.6%) 1.5 (11.7%) 0.3 (2.6%)
6 18.7 1.7 (9.1%) 2.5 (13.4%) 0.8 (4.7%)
7 23.1 3.1 (13.4%) 4.2 (18.2%) 1.1 (5.5%)
8 10.4 0.7 (6.7%) 0.7 (6.7%) 0.0 (0.0%)
9 19.3 1.1 (5.7%) 2.7 (14.0%) 1.6 (8.8%)
10 20.2 3.0 (14.9%) 3.8 (18.8%) 0.8 (4.7%)
11 17.2 1.0 (5.8%) 2.1 (12.2%) 1.1 (6.8%)
12 19.5 3.2 (16.4%) 3.3 (16.9%) 0.1 (0.6%)
13 14.2 1.2 (8.5%) 2.4 (16.9%) 1.2 (9.3%)
14 15.7 2.1 (13.4%) 2.6 (16.6%) 0.5 (3.7%)
15 27.8 3.0 (10.8%) 4.7 (16.9%) 1.7 (6.9%)
Mean 19.1 1.9 (9.7%) 2.8 (14.2%) 0.9 (4.9%)
SD 4.6 0.9 (3.4%) 1.0 (3.2%) 0.5 (2.7%)
PTV = planning target volumeRadiation Oncology 2006, 1:8 http://www.ro-journal.com/content/1/1/8
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The maximum spinal cord dose was 44.7 ± 7.4 Gy for
involved-field treatment plans generated for PTVroutine,
and non-significant reductions to 43.7 ± 7.7 Gy and 42.8
± 8.8 Gy were seen for plans based on PTVall phases and PTV-
gating.
Discussion
Attempts to improve local control in stage III NSCLC have
been confounded by an increased incidence of treatment-
related toxicity, including unexpected late toxicities such
as symptomatic bronchial stenosis, mediastinal fibrosis
and stenosis of the pulmonary artery [9,11]. The reporting
of significant lung tumor motion has led to large margins
being added to the clinical target volume to ensure ade-
quate dose coverage. As such, respiration-gated radiother-
apy is an approach that can reduce the volume of
irradiated normal tissue.
This study in 15 consecutive patients with stage III NSCLC
highlights the volumetric and dosimetric gains that can be
achieved using individualized PTVs that incorporate all
tumor motion and also respiration-gated PTVs in expira-
tory phases. Of note is the finding that significant gains
are attained simply by using individualized 4D mobility
margins (i.e. PTVall phases) instead of PTVs based upon
standard margins of 1.5 cm. The additional reductions in
lung toxicity parameters achieved with respiratory gating
were generally modest, but strongly correlated with the
reduction in tumor mobility achieved with gating. Careful
patient selection appears required to establish the optimal
benefit.
Just as for stage I NSCLC [2], the larger PTVroutine did not
achieve coverage of all mobility in 7 of the 15 patients
with tumors in upper- (n = 2), middle- (n = 2), and lower
lobes (n = 3). For the upper lobe tumors, the mobility of
mediastinal lymph nodes appeared to be inadequately
incorporated using standard margins; for the middle- and
lower lobe tumors this was the case for either the subcari-
nal nodes (n = 2), mediastinal lymph nodes (n = 3) or the
primary tumor (n = 2).
This analysis of 4DCT data revealed that reductions in
both V20 and MLD can be achieved even when GTVs
exceed 150 cc, but that this was restricted to tumors
located in middle and lower lobe. For the latter, the mean
reduction in V20 was 10.1 ± 2.7% for PTVgating relative to
PTVall phases. In contrast, recent reports suggested that dosi-
a-b Dosimetric correlation between (a) PTV reduction and V20 reduction, and (b) PTV reduction and MLD reduction Figure 2
a-b Dosimetric correlation between (a) PTV reduction and V20 reduction, and (b) PTV reduction and MLD reduction.Radiation Oncology 2006, 1:8 http://www.ro-journal.com/content/1/1/8
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metric benefits for gated radiotherapy were restricted to
patients whose GTVs were 150 cc or less, and which also
exhibited significant mobility [13]. The mean mobility in
our 15 patients (9.4 ± 6.3 mm) was similar to that of the
20 patients in the abovementioned report (9.4 ± 4.1 mm).
The potential benefits of respiratory gating must be
viewed in the light of the residual uncertainties during
gated delivery, for example the correlation between the
PTV and external respiratory surrogates [19]. As changes
in target volumes for lung cancer have been observed dur-
ing both stereotactic radiotherapy [20] and convention-
ally-fractionated radiotherapy [21], the relationship
between external markers and the PTV may have to be re-
established during treatment. Ongoing developments in
volumetric imaging at the treatment unit may increase the
accuracy of respiration-gated radiotherapy.
Another approach explored for reducing toxicity is inten-
sity-modulated radiotherapy (IMRT). A planning study
comparing IMRT and 3D conformal radiotherapy in 41
patients with locally-advanced stage NSCLC reported a
median reduction in V20 of 10% and a reduction in MLD
of ≥2 Gy [22]. However, 4D treatment planning for con-
formal radiotherapy and IMRT is in its infancy [23].
A limitation of our study is the fact that the esophagus was
contoured in only one phase of respiration position.
Recent data suggests that respiration-induced mobility of
the lower esophagus can occur [24], which can confound
our conclusions about the dosimetric impact of gated
delivery.
Conclusion
Our analysis of 4DCT data indicates that individualized
4DCT-based PTVs ensure optimal target coverage with
minimal irradiation of normal tissues in patients with
stage III NSCLC. Respiration-gated radiotherapy can fur-
ther reduce the risk of pulmonary toxicity, particularly for
tumors located in the middle and lower lobes.
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